PAN Foundation submits letter to Congress in support of cancer treatment access act
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
The PAN Foundation submitted a letter to Congressmembers Glenn Grothman and Suzanne Bonamici in support of H.R.4101, the Cancer Drug Parity Act of 2025 which expands access to breakthrough treatments for cancer.
Prescription oral chemotherapies are becoming increasingly common, with nearly 40% of all anticancer drugs in the oncology development pipeline expected to be in pill form. These treatments offer patients a transformative option to receive care and recover in the comfort of their own homes. However, despite clear clinical benefits and advances in cancer treatment, outdated insurance policies still prevent many patients from accessing their prescribed–and sometimes only–treatment option. Estimates show that oral cancer drugs can cost Medicare beneficiaries more than $11,000 a year, creating an unfair and often insurmountable barrier to care. While 43 states and the District of Columbia have enacted oral parity legislation, many Americans still lack these protections. The Cancer Drug Parity Act of 2025 will help ensure that every person fighting cancer can make treatment decisions based on what’s best for their health and reduce financial strain that has for too long limited or denied access to life-saving care.